Alphamab Oncology (SEHK:9966) - Stock Price, News & Analysis

9966 Stock Overview

A clinical stage biopharmaceutical company, engages in the research and development, manufacture, and commercialization of oncology biologics.

About the company

9966 fundamental analysis
Snowflake Score
Valuation	2/6
Future Growth	5/6
Past Performance	0/6
Financial Health	5/6
Dividends	0/6

Rewards

Trading at 90.5% below our estimate of its fair value

Earnings are forecast to grow 70.06% per year

Earnings have grown 23.2% per year over the past 5 years

Risk Analysis

No risks detected for 9966 from our risk checks.

Alphamab Oncology Competitors

Biocytogen Pharmaceuticals (Beijing)

SEHK:2315

HK$2.5b

Mabpharm

SEHK:2181

HK$1.4b

Abbisko Cayman

SEHK:2256

HK$2.1b

CK Life Sciences Int'l. (Holdings)

SEHK:775

HK$3.7b

Price History & Performance

Summary of all time highs, changes and price drops for Alphamab Oncology
Historical stock prices
Current Share Price	HK$3.06
52 Week High	HK$13.46
52 Week Low	HK$2.00
Beta	0.28
11 Month Change	20.95%
3 Month Change	27.50%
1 Year Change	-64.42%
33 Year Change	-82.65%
5 Year Change	n/a
Change since IPO	-77.33%

Recent updates

Some Alphamab Oncology (HKG:9966) Shareholders Look For Exit As Shares Take 48% Pounding

Jun 20

Alphamab Oncology's (HKG:9966) Shares Climb 27% But Its Business Is Yet to Catch Up

May 06

Optimistic Investors Push Alphamab Oncology (HKG:9966) Shares Up 27% But Growth Is Lacking

Mar 13

Subdued Growth No Barrier To Alphamab Oncology's (HKG:9966) Price

Jan 17

Slammed 40% Alphamab Oncology (HKG:9966) Screens Well Here But There Might Be A Catch

May 21

Newsflash: Alphamab Oncology (HKG:9966) Analysts Have Been Trimming Their Revenue Forecasts

Mar 01

How Many Alphamab Oncology (HKG:9966) Shares Have Insiders Sold, In The Last Year?

Feb 09

Shareholder Returns

	9966	HK Biotechs	HK Market
7D	15.0%	3.3%	9.8%
1Y	-64.4%	-15.5%	12.9%

Return vs Industry: 9966 underperformed the Hong Kong Biotechs industry which returned -15.5% over the past year.

Return vs Market: 9966 underperformed the Hong Kong Market which returned 12.9% over the past year.

Price Volatility

Is 9966's price volatile compared to industry and market?
9966 volatility
9966 Average Weekly Movement	7.0%
Biotechs Industry Average Movement	7.1%
Market Average Movement	6.6%
10% most volatile stocks in HK Market	13.6%
10% least volatile stocks in HK Market	3.5%

Stable Share Price: 9966's share price has been volatile over the past 3 months.

Volatility Over Time: 9966's weekly volatility has decreased from 12% to 7% over the past year.

About the Company

Founded	Employees	CEO	Website
2008	429	Ting Xu	www.alphamabonc.com

Alphamab Oncology, a clinical stage biopharmaceutical company, engages in the research and development, manufacture, and commercialization of oncology biologics. Its product pipeline includes KN046, a bispecific monoclonal antibody (BsAb) immune checkpoint inhibitor, that targets clinically-validated immune checkpoints, including programmed death ligand 1 (PD-L1) and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4); and KN026, a next generation anti-human epidermal growth factor receptor 2 (HER2) BsAb that is in Phase III clinical trials for treatment of HER2-positive breast cancer; and phase I and II clinical trial treatment of heavily pre-treated HER2 cancers, as well as Phase II clinical trial to treat unreselectable or metastatic HER2-positive solid tumors. The company’s product pipeline also comprises KN035, an injectable PD-L1 inhibitor that is in phase III clinical trials for neoadjuvant/adjuvant treatment of non-small cell lung cancer and endometrial cancer; and KN019, a CTLA-4-based immunosuppressant fusion protein, for auto-immune diseases and oncology treatment-induced immune disorders.

Alphamab Oncology Fundamentals Summary

How do Alphamab Oncology's earnings and revenue compare to its market cap?
9966 fundamental statistics
Market cap	HK$2.72b
Earnings (TTM)	-HK$239.19m
Revenue (TTM)	HK$283.83m

10.4x

P/S Ratio

-12.3x

P/E Ratio

Is 9966 overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
9966 income statement (TTM)
Revenue	CN¥255.87m
Cost of Revenue	CN¥52.88m
Gross Profit	CN¥202.99m
Other Expenses	CN¥418.62m
Earnings	-CN¥215.63m

Last Reported Earnings

Jun 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)	-0.22
Gross Margin	79.33%
Net Profit Margin	-84.27%
Debt/Equity Ratio	19.6%

How did 9966 perform over the long term?

See historical performance and comparison

9966 Stock Overview

Rewards

Risk Analysis

Alphamab Oncology Competitors

SEHK:2315

HK$2.5b

SEHK:2181

HK$1.4b

SEHK:2256

HK$2.1b

SEHK:775

HK$3.7b

Price History & Performance

Recent News & Updates

First half 2024 earnings released: CN¥0.047 loss per share (vs CN¥0.042 loss in 1H 2023)

Alphamab Oncology Presented the Latest Clinical Data from Two Studies on Anti-Her2 Bispecific Adc Jskn003 At the Esmo Congress 2024

Alphamab Oncology Announces Updates in Relation to A Phase III Clinical Trial of KN046 for the Treatment of Advanced SQ NSCLC

Insufficient new directors

Alphamab Oncology (SEHK:9966) commences an Equity Buyback Plan for 96,492,380 shares, representing 10% of its issued share capital, under the authorization approved on June 12, 2024.

Alphamab Oncology (SEHK:9966) commences an Equity Buyback Plan for 96,492,380 shares, representing 10% of its issued share capital, under the authorization approved on June 12, 2024.

Recent updates

First half 2024 earnings released: CN¥0.047 loss per share (vs CN¥0.042 loss in 1H 2023)

Alphamab Oncology Presented the Latest Clinical Data from Two Studies on Anti-Her2 Bispecific Adc Jskn003 At the Esmo Congress 2024

Alphamab Oncology Announces Updates in Relation to A Phase III Clinical Trial of KN046 for the Treatment of Advanced SQ NSCLC

Insufficient new directors

Alphamab Oncology (SEHK:9966) commences an Equity Buyback Plan for 96,492,380 shares, representing 10% of its issued share capital, under the authorization approved on June 12, 2024.

Alphamab Oncology (SEHK:9966) commences an Equity Buyback Plan for 96,492,380 shares, representing 10% of its issued share capital, under the authorization approved on June 12, 2024.

First half 2024 earnings released: CN¥0.047 loss per share (vs CN¥0.042 loss in 1H 2023)

Alphamab Oncology to Report First Half, 2024 Results on Aug 15, 2024

Some Alphamab Oncology (HKG:9966) Shareholders Look For Exit As Shares Take 48% Pounding

Alphamab Oncology Presents Chinese Clinical Data of Anti-HER2 Bispecific ADC JSKN003 for the First Time at the 2024 ASCO Annual Meeting

Alphamab Oncology Provides Updates in Relation to A Phase III Clinical Trial of KN046 for the Treatment of Advanced PDAC

New major risk - Share price stability

Alphamab Oncology Announces First Patient Has Been Successfully Dosed in A Phase I Clinical Trial of JSKN016

Alphamab Oncology's (HKG:9966) Shares Climb 27% But Its Business Is Yet to Catch Up

Alphamab Oncology Announces Updates on Results of a Phase I Clinical Trial of JSKN003 for the Treatment of HER2-Expressing Advanced Solid Tumors for Presentation at 2024 AACR Annual Meeting

Alphamab Oncology Presented the Dose-Escalation Results from Jskn003 in Patients with Advanced/Metastatic Solid Tumors At Aacr

New minor risk - Share price stability

Consensus revenue estimates decrease by 12%, EPS upgraded

Full year 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

No longer forecast to breakeven

Alphamab Oncology, Annual General Meeting, Jun 12, 2024

Alphamab Oncology Announces the First Patient Dosed in Australia in the Clinical Study of Subcutaneous Formulation JSKN033

Alphamab Oncology Announces Results of Phase II Clinical Study of Kn046 Plus Chemotherapy as First-Line Treatment for Metastatic Nsclc Were Published in Cell Reports Medicine

Alphamab Oncology to Report Fiscal Year 2023 Results on Mar 28, 2024

Optimistic Investors Push Alphamab Oncology (HKG:9966) Shares Up 27% But Growth Is Lacking

Alphamab Oncology Announces Results of Phase II Clinical Study of KN046 in Combination with Nab-paclitaxel in TNBC were Published in Nature Communications

Subdued Growth No Barrier To Alphamab Oncology's (HKG:9966) Price

Alphamab Oncology Announces Phase I/II Clinical Trial of Jskn033 Independently Developed by Group for the Treatment of Human Epidermal Growth Factor Receptor

Alphamab Oncology Announces First Patient Dosed in Phase Iii Study of Jskn003 for the Treatment of Advanced Her2-Low Breast Cancer

Alphamab Oncology Announces Preliminary Results of a Phase I Clinical Trial of JSKN003 in Australia for the Treatment of Her2-Expressing Advanced Solid Tumors

New major risk - Revenue and earnings growth

New minor risk - Share price stability

Alphamab Oncology and CSPC Pharmaceutical Group Co., Ltd. Jointly Receive Breakthrough Therapy Designation on KN026 by CDE

Alphamab Oncology Announces Results of Two Studies of HER2 Bispecific Antibody KN026 At the European Society of Medical Oncology

New minor risk - Profitability

First half 2023 earnings released: CN¥0.042 loss per share (vs CN¥0.16 loss in 1H 2022)

Alphamab Oncology Announces Research Updates on KN046 and KN026 for Presentation At ESMO Congress 2023

Alphamab Oncology to Report First Half, 2023 Results on Aug 23, 2023

Alphamab Oncology Announces First Patient Successfully Dosed in Randomized, Controlled, Open-Label, Multi-Center, Phase III Clinical Trial of Kn026 in China

Alphamab Oncology Resignation of Xu Zhan Kevin as Non-Executive Director and Member of the Strategy Committee

Alphamab Oncology Updates Clinical Research Data for Kn026 in Combination with Kn046 in Her2-Positive Solid Tumors At the Asco 2023 Annual Meeting

Slammed 40% Alphamab Oncology (HKG:9966) Screens Well Here But There Might Be A Catch

Alphamab Oncology Updates in Relation to A Phase Iii Clinical Trial of Kn046 for the Treatment of Advanced SQ NSCLC

Consensus revenue estimates decrease by 13%, EPS upgraded

No longer forecast to breakeven

Newsflash: Alphamab Oncology (HKG:9966) Analysts Have Been Trimming Their Revenue Forecasts

Consensus revenue estimates decrease by 15%

Alphamab Oncology has completed a Follow-on Equity Offering in the amount of HKD 380.5 million.

Forecast to breakeven in 2025

Alphamab Oncology Presents Clinical Data of Kn026 Combined with Docetaxel as Neoadjuvant Treatment for Her2-Positive Early or Locally Advanced Breast Cancer At Sabcs 2022

Alphamab Oncology Presented Final Analysis of KN046 Combined with Nab-paclitaxel in the Treatment of mTNBC at SABCS 2022

Alphamab Oncology Announces Results from Three Clinical Studies of KN026 and KN046

Alphamab Oncology Receives IND Approval by NMPA for A Phase Ia/Ib Clinical Trial of JSKN003 for the Treatment of Advanced Solid Tumors

Is Alphamab Oncology (HKG:9966) Using Debt Sensibly?

Alphamab Oncology Announces First Patient Dosed in A Phase I Clinical Trial of JSKN003 (KN026-ADC) in Australia for the Treatment of Advanced Solid Tumors

Alphamab Oncology Presents the updated data from Phase 2 Clinical trial on KN046 Combined with platinum doublet chemotherapy as first-line(1L)treatment for NSCLC at ESMO 2022

Alphamab Oncology Announces Updates on Clinical Data of KN046 and KN026

Alphamab Oncology Announces Updates on Clinical Data of KN046 and KN026

Alphamab Oncology to Report First Half, 2022 Results on Aug 31, 2022